DDInter626 DDInter200
Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, affecting 72% of all chronic HCV patients. Treatment options for chronic hepatitis C have advanced significantly since 2011, with the development of direct-acting antivirals (DAAs) such as elbasvir. Elbasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly.[synthesis] The barrier to the development of resistance to NS5A inhibitors is lower than that of NS5B inhibitors, another class of DAAs. Substitutions at amino acid positions 28, 30, 31, or 93 are known to confer resistance to elbasvir. Despite this
Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients .
Betrixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Betrixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Betrixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amprenavir
Betrixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Berotralstat
Betrixaban {u} may lead to a major life threatening interaction when taken with {v} Iloprost
Betrixaban {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Betrixaban may cause a minor interaction that can limit clinical effects when taken with Clove
Betrixaban may cause a minor interaction that can limit clinical effects when taken with Turmeric
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Betrixaban may lead to a major life threatening interaction when taken with Iloprost
Betrixaban may lead to a major life threatening interaction when taken with Avapritinib